Bridging the Gaps in GIST Care
GIST patients often face unequal care due to gaps in specialist access, biomarker testing, and education, underscoring the need to make expert, equitable treatment the standard rather than the exception.
Know Your Mutation: Why is Biomarker Testing Important in GIST?
Michelle Harris and Calvin Chao of Tempus will discuss the importance of biomarker testing in GIST, the process of biomarker testing, how to get testing done for free through The LRG, and more.
European Patient Cancer Coalition Publishes Patient Guide for Cancer Biomarkers
European Patient Cancer Coalition published Patient Guide for Cancer Biomarkers in January 2023.
Our Latest Publication Focused on Mutational Testing
The LRG published "Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of Life Raft Group members" in BMC Gastroenterology, November 2022.
Collaborative Effort Produces Position Paper on Need for Advanced Biomarker Testing
The Life Raft Group was recently part of team of authors on a collaborative position paper entitled 'Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type published' in Pathology: The Journal of the Royal College of Pathologists of Australia.
The Importance of Biomarker Testing
The Life Raft Group partnered with Dr. Michael Wagner of the University of Washington to present “The Importance of Biomarker Testing” to GIST patients and caregivers on August 12th, 2022.
Did You Know? Tissue Testing FREE for GIST Patients!
The Life Raft Group is currently conducting a tissue testing initiative for GIST patients to receive FREE Next-Generation Sequencing (NGS) Testing!
The Importance of Biomarker Testing
August 12th, 12-1pm ET The Life Raft Group is partnering with Dr. Michael Wagner from the University of Washington to present “The Importance of Biomarker Testing” to GIST patients and caregivers on August 12th, [...]
Perspectives in Biomarker Testing
This video is about understanding the role of mutations and biomarker testing in GIST. Knowing the driving force behind each individual’s tumors is not just important, it is critical in determining the most effective treatment for your mutation.
The Importance of Biomarker Testing for the Effective Treatment of GIST Patients – LRG Science
This issue of LRG Science presents six case studies as evidence that the practice of biomarker/mutational testing early in a GIST patient's journey is a critical path to the most effective treatment. Each patient was diagnosed with GIST, but did not receive mutational testing early enough to avoid suffering adverse side effects and wasting money on unnecessary, costly drugs.